Dual treatment of these cell lines with bemcentinib and UNC2025, a MerTK-directed TKI, significantly inhibited tumor cell expansion in vitro and impacted tumor growth in vivo compared with single inhibition of Axl or MerTK alone. Here, AXL is linked to neoplasm.